Interpace Biosciences, Inc.
- IDXG ยท OTC
- Surgical & Medical Instruments & Apparatus
- Parsippany, NJ
- 102 employees
- CIK 0001054102
Updated from SEC filings through
Top things to know
Executives
-
Thomas W. Burnell CEO, President & Chairman 4, 2026-08-20 -
Christopher McCarthy CFO & COO 4, 2026-08-20
Interpace Biosciences, Inc. is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Parsippany, NJ. It trades as IDXG on OTC. Revenue was $38.7M in the fiscal year ending December 31, 2025, -17.5% from the year before. It reported about 102 employees. Thomas W. Burnell is CEO, President & Chairman.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $38.7M 10-K, 2026-03-30 | $46.9M 10-K, 2026-03-30 | $40.0M 10-K, 2025-03-31 | $5.7M 10-K, 2023-03-27 | $8.2M 10-K, 2023-03-27 |
| Operating income | $4.1M 10-K, 2026-03-30 | $8.1M 10-K, 2026-03-30 | $4.0M 10-K, 2025-03-31 | -$3.6M 10-K, 2024-04-01 | -$6.3M 10-K, 2023-03-27 |
| SG&A | $19.4M 10-K, 2026-03-30 | $21.1M 10-K, 2026-03-30 | $19.6M 10-K, 2025-03-31 | $20.1M 10-K, 2024-04-01 | $19.9M 10-K, 2023-03-27 |
| Net income | $24.6M 10-K, 2026-03-30 | $6.7M 10-K, 2026-03-30 | $2.0M 10-K, 2025-03-31 | -$22.0M 10-K, 2024-04-01 | -$14.9M 10-K, 2023-03-27 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Thomas W. Burnell | CEO, President & Chairman | 4, 2026-08-20 |
| Christopher McCarthy Chief Financial Officer & Chief Operating Officer at Interpace Biosciences | CFO & COO | 4, 2026-08-20 |
What Interpace Biosciences, Inc. does
Clinical services that help guide patient management decisions by providing information on the diagnosis and prognosis of indeterminate specimens. Guidance on genetic marker-related pharmaceutical treatment options, when available, is also provided.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 27.7 million (as of July 31, 2026) | 10-Q, August 10, 2026 |
|---|---|---|
| Public float | $2.6M (as of June 30, 2025) | 10-K/A, April 30, 2026 |
| Reportable segments | 1 (period ending December 31, 2025) | 10-K, March 30, 2026 |
| Latest proxy statement | Meeting July 7, 2026 (filed July 7, 2026) | DEF 14A, July 7, 2026 |
| Auditor | Eisneramper LLP (Philadelphia, Pennsylvania) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-10-15
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-27
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-21
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-08-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-14
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-01
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-20
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-12-03
- Item 8.01 Other events
- 8-K filed 2025-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-08-08
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Interpace Biosciences, Inc.
- What does Interpace Biosciences, Inc. do?
- In its own words, from Item 1 of its 10-K: "Clinical services that help guide patient management decisions by providing information on the diagnosis and prognosis of indeterminate specimens. Guidance on genetic marker-related pharmaceutical treatment options, when available, is also provided."
- What is Interpace Biosciences, Inc.'s revenue?
- $38.7M for the fiscal year ending December 31, 2025, from its 10-K filed March 30, 2026.
- Is Interpace Biosciences, Inc. profitable?
- Interpace Biosciences, Inc. reported net income of $24.6M for the fiscal year ending December 31, 2025.
- How many employees does Interpace Biosciences, Inc. have?
- About 102 as of March 2, 2026, as stated in its annual report.
- Who is the CEO of Interpace Biosciences, Inc.?
- Thomas W. Burnell, CEO, President & Chairman, as named in a 4 filed August 20, 2026.
- Who is the CFO of Interpace Biosciences, Inc.?
- Christopher McCarthy, CFO & COO, as named in a 4 filed August 20, 2026.
- Where is Interpace Biosciences, Inc. headquartered?
- Parsippany, NJ.
- What is Interpace Biosciences, Inc.'s stock ticker?
- IDXG on OTC.
- What industry is Interpace Biosciences, Inc. in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Interpace Biosciences, Inc.'s website?
- interpace.com. Investor relations: https://ir.interpace.com.
- When does Interpace Biosciences, Inc. report earnings next?
- November 11, 2026. Source: estimate_10q_cadence.
- Is Interpace Biosciences, Inc. a public company?
- Yes. Interpace Biosciences, Inc. files with the SEC under CIK 0001054102 and trades as IDXG.
- Who audits Interpace Biosciences, Inc.?
- Eisneramper LLP, Philadelphia, Pennsylvania, as named in its latest annual report (10-K).
- How many shares of Interpace Biosciences, Inc. are outstanding?
- 27.7 million shares as of July 31, 2026, from its 10-Q filed August 10, 2026.
- What is Interpace Biosciences, Inc.'s public float?
- $2.6M as of June 30, 2025, as reported on the cover of its 10-K/A filed April 30, 2026.
- How many business segments does Interpace Biosciences, Inc. report?
- 1 reportable segment for the period ending December 31, 2025, from its 10-K filed March 30, 2026.
- When is Interpace Biosciences, Inc.'s annual shareholder meeting?
- July 7, 2026, per its proxy statement (DEF 14A) filed July 7, 2026.